AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation's leading business incubators dedicated to life sciences and biotechnology
該公司與位於北布倫瑞克的國家支持的新澤西生物科學中心簽訂了一項租賃協議，該中心是美國領先的生命科學和生物技術企業孵化器之一
New Jersey Bioscience Center, NJ
新澤西州新澤西州生物科學中心
OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced today it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot R&D facility at the New Jersey Bioscience Center ("NJBC").
佛羅裏達州奧卡拉，2022年6月21日(環球通訊社)AIM免疫科技公司(紐約證券交易所代碼：American AIM)(“AIM”或“公司”)是一家專注於治療多種癌症、免疫紊亂和病毒性疾病(包括新冠肺炎，由SARS-CoV-2病毒引起的疾病)的免疫製藥公司，該公司今天宣佈，它已與新澤西州經濟發展局簽訂了一份租賃協議，將在新澤西州生物科學中心(“新澤西州生物科學中心”)建設一個5,210平方英尺的研發設施。
AIM Chief Executive Officer Thomas K. Equels commented, "The AIM team is pleased to join a number of thriving, prestigious life sciences companies at the NJBC. This state-of-the-art facility will help us to continue to advance our research and development of Ampligen to treat multiple types of cancers, immune disorders, and viral diseases. We have made a significant investment in new equipment for this facility and believe that this space will enhance our future development progress."
AIM首席執行官Thomas K.Equels表示：“AIM團隊很高興加入NJBC眾多蓬勃發展的著名生命科學公司。這個最先進的設施將幫助我們繼續推進Ampligen的研究和開發，以治療多種類型的癌症、免疫疾病和病毒性疾病。我們已經為這個設施的新設備進行了大量投資，並相信這個空間將促進我們未來的開發進程。”
The New Jersey Bioscience Center is a 50-acre research park home to a number of successful biotech businesses. The Incubator at North Brunswick is the leading incubator for small businesses in the region dedicated to life sciences and biotechnology companies. The NJBC has invested over $70 million in facilities and improvements to its campus.
About AIM ImmunoTech Inc.
新澤西生物科學中心是一個佔地50英畝的研究園區，是許多成功的生物技術企業的所在地。北不倫瑞克的孵化器是該地區致力於生命科學和生物技術公司的小型企業的領先孵化器。NJBC已經投資了超過7000萬美元來改善校園的設施和設施。
關於AIM免疫技術公司
AIM ImmunoTech Inc. is an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company's lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.
目的免疫科技公司是一家免疫製藥公司，專注於研究和開發治療多種類型的癌症、免疫紊亂和病毒性疾病的療法，包括新冠肺炎。該公司的主導產品Ampligen®(Rintatolimod)是一種具有廣譜活性的免疫調節劑，正在開發中，用於治療全球重要的癌症、病毒性疾病和免疫系統疾病。
Ampligen is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM plans to initiate a Phase 2 clinical study in 2022. The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. Additionally, Ampligen is approved in Argentina for the treatment of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 treatments and COVID-19 Long Hauler treatment.
Ampligen目前正被用作治療胰腺癌患者的單一療法，該計劃由荷蘭醫療檢查局在伊拉斯謨醫學中心批准，AIM計劃在2022年啟動一項第二階段臨牀研究。該公司還正在進行多項臨牀試驗，以評估Ampligen作為一種組合療法，用於治療各種實體腫瘤類型，這些試驗正在和計劃在主要癌症研究中心進行。此外，Ampligen在阿根廷被批准用於治療肌肉痛腦脊髓炎/慢性疲勞綜合徵(ME/CFS)，目前正在接受SARS-CoV-2/新冠肺炎療法和新冠肺炎Long Hauler療法的多方面評估。
For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.
欲瞭解更多信息，請訪問aimevi.com，並在Twitter、LinkedIn和Facebook上與該公司聯繫。
Cautionary Statement
警示聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
本新聞稿包含“1995年私人證券訴訟改革法”(“PSLRA”)所指的前瞻性陳述。諸如“可能”、“將”、“預期”、“計劃”、“預期”和類似的表述(以及涉及未來事件或情況的其他詞語或表述)旨在識別前瞻性表述。其中許多前瞻性陳述涉及許多風險和不確定因素。此外，對於這些陳述，該公司聲稱為PSLRA中包含的前瞻性陳述提供了安全保護。公司不承諾更新這些前瞻性陳述中的任何一項，以反映在本新聞稿發佈之日之後發生的事件或情況。
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com
投資者關係聯繫人
JTC團隊，有限責任公司
珍妮·託馬斯
833-475-8247
郵箱：Aim@jtCir.com
A photo accompanying this announcement is available at
這一公告附帶的照片可在以下網址查閲
譯文內容由第三人軟體翻譯。